000			02230 a2200625 4500
005			20250518020155.0
264		0	_c20190625
008			201906s 0 0 eng d
022			_a2352-3964
024	7		_a10.1016/j.ebiom.2018.12.032 _2doi
040			_aNLM _beng _cNLM
100	1		_aLiu, Chun-Yu
245	0	0	_aTargeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression. _h[electronic resource]
260			_bEBioMedicine _cFeb 2019
300			_a263-275 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aAutoantigens _xgenetics
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aCisplatin _xpharmacology
650	0	4	_aDNA-Binding Proteins
650	0	4	_aDisease Models, Animal
650	0	4	_aErlotinib Hydrochloride _xpharmacology
650	0	4	_aExtracellular Signal-Regulated MAP Kinases _xantagonists & inhibitors
650	0	4	_aFemale
650	0	4	_aGene Expression Regulation, Neoplastic _xdrug effects
650	0	4	_aHistone Chaperones _xmetabolism
650	0	4	_aHumans
650	0	4	_aIntracellular Signaling Peptides and Proteins
650	0	4	_aMembrane Proteins _xgenetics
650	0	4	_aMice
650	0	4	_aModels, Biological
650	0	4	_aPromoter Regions, Genetic
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProtein Phosphatase 2 _xmetabolism
650	0	4	_aProto-Oncogene Proteins c-akt _xmetabolism
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aTranscription Factors _xmetabolism
650	0	4	_aTriple Negative Breast Neoplasms _xgenetics
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aHuang, Tzu-Ting
700	1		_aChen, Yi-Ting
700	1		_aChen, Ji-Lin
700	1		_aChu, Pei-Yi
700	1		_aHuang, Chun-Teng
700	1		_aWang, Wan-Lun
700	1		_aLau, Ka-Yi
700	1		_aDai, Ming-Shen
700	1		_aShiau, Chung-Wai
700	1		_aTseng, Ling-Ming
773	0		_tEBioMedicine _gvol. 40 _gp. 263-275
856	4	0	_uhttps://doi.org/10.1016/j.ebiom.2018.12.032 _zAvailable from publisher's website
999			_c29262090 _d29262090